• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

New therapy DT2216 tackles tough-to-treat ovarian cancer

by Marisa Wexler, MS | Dec 3, 2025 | Myeloma News

A new experimental therapy, DT2216, has begun testing in a clinical trial for people with hard-to-treat ovarian cancer, a significant step forward announced by Dialectic Therapeutics. The Phase 1b/2 study (NCT06964009) is targeting patients whose disease is relapsed...

Characterizing circulating rare cells in peripheral blood for detecting and monitoring multiple myeloma and precursor states

by MM360 Staff | Dec 3, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

California myeloma clinic reports ‘unprecedented’ patient survival

by Marisa Wexler, MS | Dec 2, 2025 | Myeloma News

Most myeloma patients who started treatment at the Berenson Cancer Center — a clinic in California that specializes in myeloma care — lived for more than a decade after beginning treatment, according to a new study published by scientists at the center. Their...

Targeting RNA polymerase I to boost natural killer cell anticancer activity in multiple myeloma

by MM360 Staff | Nov 29, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

by MM360 Staff | Nov 29, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

by MM360 Staff | Nov 27, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis
  • (no title)
  • (no title)
  • (no title)
  • Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma
  • Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis
  • (no title)
  • Measurable residual disease assessment in multiple myeloma
  • Oncolytics to test immunotherapy against aggressive pancreatic cancer
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT